innovative medicines initiative (imi): digital information · 2015-06-10 · created the open...
TRANSCRIPT
Innovative Medicines Initiative (IMI): digital information
Colm Carroll
10 July 2015 | Towards digital health, EESC, Bruxelles
IMI – Europe’s partnership for health
> €5 bn
Partnership
2008 - 2024
€2.5 bn
€2.5 bn
Inclusion of real life
medical practice
(2014 SRA – IMI 2)
Inclusion of society /
healthcare challenges
(2011 SRA)
Evolution of IMI
Idea
generation
Daily
medical
practice
Regulatory
approval
HTA &
Pharmaco-
vigilance
Basic
research
Non-clin.
testing
Human
testing
Focus of early
IMI Calls
(2008 SRA)
An international, cross-sector community
~ 850 academic
teams
~ 170 SMEs
~ 480 EFPIA teams
~ 25 patient orgs
~ 20 regulators
Over 7 000 researchers
working for:
open collaboration
improved R&D
productivity
innovative approaches
to unmet medical
needs
IMI Data and Knowledge Management Enabling Platforms
Research
Informatics Translational
Informatics
Real World
Data
Adaptive
Informatics
IMI
IMI-2
Adaptive
Infrastructure RADAR
BD4BOs
Open
Biomarker
Repository
Smart Clinical
Program
Design Patient
Hub
eTOX2
N
OH
OH
N
O
N
OH
Publically available toxicology data
Reports from companies
Searchable in a database
Development of reliable toxicity predictive systems
Predictive in-silico models
Created the Open PHACTS Discovery Platform linking information
and facts from multiple public databases
Created an API for drug discovery with an ecosystem of apps
the Open PHACTS Foundation – support the existing infrastructure
and widen scientific scope
Compound Target Pathway Disease data
European Medical Information Framework
Platform
Make data available for
browsing and analysis in
multiple ways
Alzheimers Disease
Identification and validation of
markers that predict
Alzheimer’s progression
Metabolics
Discovery of predictors of the
metabolic complications of
adult and paediatric obesity
Mobile and Social Technology for Pharmacovigilance
• Direct patient reporting apps
• English, French and Spanish language analysed
• Consortium keen for global applicability
• What else can social media tell us - Abuse?
- Misuse?
- Counterfeit?
• Geo pharmacovigilance a possibility?
RADAR: Challenges in Managing Chronic Disease Today
Physician visits are time-limited evaluations based on subjective
observations of both the patient and the physician or psychiatrist
Changes in disease state for each of these diseases can occur on
timescales much shorter than the interval between physician visits
Through technological advances over the last decade it is now possible
to objectively, remotely, and continuously measure aspects of patient
physiology, behavior and symptoms
11
RADAR: Vison of tomorrow
12
Multi-Platform Biomarker
Data from
Controlled Studies
Physician Notes
Caregiver
Reports
Literature Patents Epidemiology
Company Reports E-mail
Patient Hospital Records Data
MOVE FROM DIAGNOSE AND TREAT TO PREDICT AND PREEMPT
Point of Care Data
(e.g. Adherence Assessment
or Therapeutic Monitoring)
12
Continuous Real-Time Patient Data
Home Monitoring. Remote Sensing.
(Actigraphy, Physiological)
Predict and Preempt:
relapse in depression
exacerbation in MS
Psychotic break
Epileptic fit
Bipolar State Transitions
Big data for better health outcomes
Build a stronger evidence base for the evolution towards outcome
focus through:
definition of outcomes that matter to patients
capture comparable outcomes data.
development analytic tools
identification/testing of pathways to implement outcome
evidence into R&D and medical practice
